Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Clarke, Jeffrey Melson
Wang, Xiaofei F.
Gu, Lin
Stevenson, Marvaretta Miesha
Stinchcombe, Tom
Ramalingam, Sundhar
Antonia, Scott Joseph
Shariff, Afreen
Garst, Jennifer
Crawford, Jeffrey
Ready, Neal E.
机构：
[1] Duke Canc Inst, Durham, NC USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA
[4] Duke Univ, Sch Med, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21683
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial
    Clarke, Jeffrey M.
    Gu, Lin
    Wang, Xiaofei F.
    Stinchcombe, Thomas E.
    Stevenson, Marvaretta M.
    Ramalingam, Sundhar
    Shariff, Afreen
    Garst, Jennifer
    Nixon, Andrew B.
    Antonia, Scott J.
    Crawford, Jeffrey
    Ready, Neal E.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 3 (06):
  • [2] Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)
    Zalcberg, JR
    Bishop, JF
    Millward, MJ
    Zimet, A
    Laird, J
    Barter, C
    Seward, D
    McKeage, MJ
    Friedlander, ML
    Toner, G
    Berille, J
    Blanc, C
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1084 - 1084
  • [3] Combination therapy of envafolimab and suvemcitug with chemotherapy in patients with non-small cell lung cancer (NSCLC): Results from a phase II clinical trial
    Wu, C.
    Wu, L.
    Meng, X.
    Wang, Y.
    Fan, Q.
    Wang, X.
    Gu, K.
    Ma, R.
    Hu, C.
    Lu, L.
    Su, F.
    Yang, C.
    Liu, Z.
    Tian, J.
    Sun, X.
    Sun, S.
    Cheng, Y.
    ANNALS OF ONCOLOGY, 2023, 34
  • [4] Clinical outcome of nivolumab and ipilimumab in untreated advanced non-small cell lung cancer patients
    Sugimoto, Akira
    Kaneda, Hiroyasu
    Nagamine, Hiroaki
    Nakahama, Kenji
    Ogawa, Koichi
    Matsumoto, Yoshiya
    Sawa, Kenji
    Tani, Yoko
    Mitsuoka, Shigeki
    Kimura, Tatsuo
    Kawaguchi, Tomoya
    ANNALS OF ONCOLOGY, 2023, 34 : S1451 - S1451
  • [5] Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients
    Veluswamy, R.
    Bhalla, S.
    Samstein, R.
    Marron, T.
    Gomez, J. E.
    Doroshow, D. B.
    Sabari, J.
    Shum, E.
    Saxena, A.
    Namakydoust, A.
    Chachoua, A.
    Wisnivesky, J.
    Mandeli, J.
    Bhardwaj, N.
    Hirsch, F. R.
    Merad, M.
    Reddy, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1019 - S1020
  • [6] Comorbidity in clinical trial patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Kosov, Maxim
    Kumar, Akhil
    Belotserkovskiy, Maxim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Phase II clinical trial of Gemcitabine and ifosfamide in inoperable non-small cell lung cancer (NSCLC)
    Cubedo, R
    Espana, P
    Provencio, M
    Jorge, M
    Sanchez, A
    ANNALS OF ONCOLOGY, 1998, 9 : 103 - 103
  • [8] A phase II trial of combination chemotherapy with irinotecan and amrubicin in pretreated patients with non-small cell lung cancer (NSCLC): Results of Okayama Lung Cancer Study Group Trial 0402
    Kuyama, S.
    Segawa, Y.
    Nogami, N.
    Kiura, K.
    Takigawa, N.
    Shibayama, T.
    Hosokawa, S.
    Aoe, K.
    Tabata, M.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
    Besse, B.
    Adam, J.
    Cozic, N.
    Chaput-Gras, N.
    Planchard, D.
    Mezquita, L.
    Remon Masip, J.
    Lavaud, P.
    Naltet, C.
    Gazzah, A.
    de Montpreville, V. Thomas
    Ghigna, M. -R.
    Mussot, S.
    Fadel, E.
    Mabille, L.
    Duchemann, B.
    Barlesi, F.
    Soria, J-C.
    Caramella, C.
    Mercier, O.
    ANNALS OF ONCOLOGY, 2020, 31 : S794 - S795
  • [10] Biweekly carboplatin and gemcitabine for untreated advanced non-small cell lung cancer (NSCLC). A multicenter phase II trial
    Domine, M
    Gomez, RG
    Firvida, J
    Delgado, J
    Estevez, L
    Docampo, LI
    Leon, A
    Pachon, V
    Casado, V
    Lobo, F
    LUNG CANCER, 2005, 49 : S242 - S242
12345